These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 26492180)

  • 1. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
    Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
    Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Profiles of Mixed Endometrial Carcinoma.
    Matrai C; Motanagh S; Mirabelli S; Ma L; He B; Chapman-Davis E; Kurtis B; Elemento O; Mosquera JM; Ellenson LH
    Am J Surg Pathol; 2020 Aug; 44(8):1104-1111. PubMed ID: 32604171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
    Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
    Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
    Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
    Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components.
    Rossi ED; Bizzarro T; Monterossi G; Inzani F; Fanfani F; Scambia G; Zannoni GF
    Hum Pathol; 2017 Apr; 62():99-107. PubMed ID: 28041971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
    Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
    Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
    Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
    Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features.
    Espinosa I; D'Angelo E; Palacios J; Prat J
    Am J Surg Pathol; 2016 Jul; 40(7):972-81. PubMed ID: 26975040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted mutation analysis of endometrial clear cell carcinoma.
    Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial Adenocarcinomas With Significant Mucinous Differentiation: A Characterization of Intratumoral Heterogeneity of KRAS Mutations in Mucinous and Endometrioid Histologic Components.
    Jackson CL; Hang S; Hansen K; He M; Sung CJ; Quddus MR; Xiong M; Wang Y; Patel NR; Lawrence WD; Xiong J
    Int J Gynecol Cancer; 2018 Feb; 28(2):241-247. PubMed ID: 29303928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Despite Diagnostic Morphology, Many Mixed Endometrial Carcinomas Show Unexpected Immunohistochemical Staining Patterns.
    Matrai CE; Pirog EC; Ellenson LH
    Int J Gynecol Pathol; 2018 Sep; 37(5):405-413. PubMed ID: 29019871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences.
    Gatius S; Cuevas D; Fernández C; Roman-Canal B; Adamoli V; Piulats JM; Eritja N; Martin-Satue M; Moreno-Bueno G; Matias-Guiu X
    Pathobiology; 2018; 85(1-2):35-40. PubMed ID: 28614814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.
    Graham RP; Kerr SE; Butz ML; Thibodeau SN; Halling KC; Smyrk TC; Dina MA; Waugh VM; Rumilla KM
    Am J Surg Pathol; 2015 Oct; 39(10):1370-6. PubMed ID: 26099011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.